Develops drugs for viral diseases like herpes and hepatitis.
Dec 2025Revenue $72.3M/yrExpenses $84.4M/yr
No trendCash runway ≈ 8.3 years from Jun 2026
Figures by year
When will Assembly Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $72.3M and expenses $84.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $72.3M | $84.4M | −$12.1M |
| Dec 2024 | $28.5M | $73.9M | −$45.4M |
| Dec 2023 | $7.16M | $71.8M | −$64.6M |
| Dec 2022 | $0.00 | $94.1M | −$94.1M |
| Dec 2021 | $6.25M | $139M | −$133M |
| Dec 2020 | $79.1M | $144M | −$64.8M |
| Dec 2019 | $16.0M | $119M | −$103M |
| Dec 2018 | $14.8M | $108M | −$92.7M |
| Dec 2017 | $9.02M | $61.2M | −$52.2M |
| Dec 2016 | $0.00 | $45.3M | −$45.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.